Table 2.
Characteristics of 72 patients according to the respectability classification
| Factors | R (n = 29) | BR (n = 23) | LA (n = 20) | p value |
|---|---|---|---|---|
| Age (years) | 72 (44–87) | 70 (51–80) | 70 (45–85) | 0.725 |
| Gender (male / female) | 15 / 14 | 12 / 11 | 16 / 4 | 0.094 |
| Patients with biliary drainage (%) | 25 (86.2%) | 16 (69.6%) | 17 (85.0%) | 0.270 |
| Initial blood examination | ||||
| Neutrophil-to-lymphocyte ratio (NLR) | 2.03 (0.97–8.15) | 2.21 (1.14–7.90) | 3.15 (0.98–10.59) | 0.083 |
| Prognostic nuritional index (PNI) | 42.5 (33.9–55.6) | 44.6 (35.2–56.2) | 42.4 (32.7–54.8) | 0.566 |
| CEA (mg/dl) | 3.6 (0.7–38.4) | 3.6 (0.9–16.3) | 4.1 (1.6–65.7) | 0.625 |
| CA19–9 (U/ml) | 100.7 (7.0–7898) | 98.4 (1.0–9066) | 208 (5.2–5265) | 0.889 |
| Initial clinical staging | ||||
| Patients with cT4 (%) | 2 (6.9%) | 16 (69.6%) | 17 (85.0%) | < 0.001* |
| Patients with clinical LN metastasis (%) | 7 (24.1%) | 7 (30.4%) | 10 (50.0%) | 0.158 |
| Patients with neoadjuvant GS therapy (%) | 8 (27.6%) | 21 (91.3%) | 18 (90.0%) | < 0.001* |
| Completion rate of initial 2 cycles (%) | 7/8 (87.5%) | 20/21 (95.2%) | 16/18 (88.9%) | |
| Median relative dose intensity of S-1 (%) | 100% | 100% | 100% | |
| Median relative dose intensity of G (%) | 101% | 87.4% | 81.8% | |
| Patients with adverse events (%) | 7 (87.5%) | 14 (66.7%) | 14 (77.8%) | |
| Toxicity grade 1/2 | 4 | 2 | 6 | |
| Toxicity grade 3/4 (grade 3 cholangitis) | 3 (2) | 12 (10) | 8 (6) | |
| Patients with resection (%) | 26 (89.7%) | 17 (73.9%) | 6 (30.0%) | < 0.001** |
R resectable, BR borderline resectable, LA locally advanced * R vs. BR, UR, **R, BR vs. UR
CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, GS gemcitabine plus S-1, LN lymph node, G gemcitabine